Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Therapy Area topics
Cardiovascular
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Pfizer starts to put its vaccine cash to use
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
Central Nervous System
Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Diabetes
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Digital Health
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Oncology
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Respiratory
JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Various
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.